Menu
Recruiting NCT07646197

Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease

No phase Interventional MASLD Fatty Liver

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Peanut consumption.
Who it may be relevant to
Registry conditions: MASLD, Fatty Liver. Basic parameters: 30 years — 70 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Impacts of Peanut Intake on Hepatic Markers and Gut Microbiota in Adults With MASLD

Overview

The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver. * Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm. * Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention * Daily log to be completed for tracking peanut consumption * 2-day Dietary recall at baseline, during Week 6 and Week 12 * Poat intervention Fibro scans for participants with baseline scans available

Interventions

  • Other Peanut consumption
    MASLD patients will consume 50 gm of peanut daily for 12 weeks

Primary outcome measures

  • Hepatic Markers [Time frame: Baseline to post-intervention (12 weeks)]
Secondary outcome measures (3)
  • Metabolic Profile [Time frame: Baseline to post-intervention (12 weeks)]
  • Gut microbiota composition [Time frame: Baseline to post-intervention (12 weeks)]
  • Intrahepatic fat content [Time frame: Baseline to post-intervention (12 weeks)]

Eligibility criteria

Inclusion criteria

  • 30-70 years
  • do not consume peanut/peanut butter/treenut/seeds > /week
  • at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
  • Able to understand, speak, and read English
  • Mentally competent to consent

Exclusion criteria

  • Food allergy to peanuts or peanut-containing products
  • With alcohol use disorder (AUDIT screening)
  • Leukemia
  • Lymphoma
  • Other types of cancer
  • Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
  • Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • Henry Ford Health System — Detroit

Identifiers

NCT: NCT07646197 · 19113 · F20581

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗